Lonza Group AG Share Price

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Market Closed - Swiss Exchange 16:31:29 15/04/2024 BST 5-day change 1st Jan Change
534 CHF -0.19% Intraday chart for Lonza Group AG -4.27% +50.98%

Financials

Sales 2024 * 6.64B 7.27B 584B Sales 2025 * 7.45B 8.15B 654B Capitalization 38.58B 42.24B 3,391B
Net income 2024 * 905M 991M 79.54B Net income 2025 * 1.11B 1.21B 97.47B EV / Sales 2024 * 6.13 x
Net Debt 2024 * 2.18B 2.38B 191B Net Debt 2025 * 2.47B 2.7B 217B EV / Sales 2025 * 5.51 x
P/E ratio 2024 *
43.2 x
P/E ratio 2025 *
34.7 x
Employees 18,000
Yield 2024 *
0.84%
Yield 2025 *
0.97%
Free-Float 95.87%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Lonza Group AG

1 day-0.30%
1 week-4.27%
Current month-1.15%
1 month+12.66%
3 months+44.09%
6 months+25.32%
Current year+50.98%
More quotes
1 week
530.80
Extreme 530.8
557.60
1 month
474.60
Extreme 474.6
559.40
Current year
339.00
Extreme 339
559.40
1 year
308.60
Extreme 308.6
599.40
3 years
308.60
Extreme 308.6
785.40
5 years
290.30
Extreme 290.3
785.40
10 years
81.85
Extreme 81.85
785.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 24/04/17
Director of Finance/CFO 52 30/11/21
Chief Operating Officer 55 31/07/22
Members of the board TitleAgeSince
Director/Board Member 63 15/04/14
Director/Board Member 66 15/04/14
Director/Board Member 58 04/05/22
More insiders
Date Price Change Volume
15/04/24 534 -0.19% 118,176
12/04/24 535 -0.96% 151,712
11/04/24 540.2 +0.90% 134,226
10/04/24 535.4 -1.76% 224,871
09/04/24 545 -2.29% 170,141

Delayed Quote Swiss Exchange, April 15, 2024 at 04:31 pm

More quotes
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
535 CHF
Average target price
566 CHF
Spread / Average Target
+5.79%
Consensus